News
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
17hon MSN
RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...
Vaccination was cost saving for participants aged 65 years and older. In phase 2 analyses, an additional dose was ...
German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...
The move drew sharp criticism from medical and health experts. “Scrapping the fastest platform we have is a reckless move ...
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...
HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...
On Tuesday, the US Department of Health and Human Services disclosed the end of funding for 22 mRNA vaccine projects — a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results